DNTH · Dianthus Therapeutics, Inc. /DE/ · Executive Compensation
$88.90
+0.85 (+0.97%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the "issuance date") As of the issuance date, the Company expects that its existing cash, cash equivalents and investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date.”View the 10-Q filed Aug 4, 2026
Market Cap
$5.23B
Shares
55.93M
Volume · Oct 1
767.07K
Avg daily vol (3M)
833.35K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Marino Garcia | President and Chief Executive Officer | $10,614,702 |
| Simrat Randhawa | Executive Vice President, Head of Research and Development | $5,221,537 |
| Ryan Savitz | Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | $5,074,953 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Marino Garcia | President and Chief Executive Officer | $8,843,300 |
| Simrat Randhawa | Chief Medical Officer | $4,035,266 |
| Ryan Savitz | Chief Financial Officer, Chief Business Officer and Treasurer | $4,002,145 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stephen Mahoney | Former President, Chief Financial and Operating Officer | $1,656,676 |
| Thomas Beetham | Former Chief Legal Officer | $1,571,434 |
| Lisa Olson | Former Chief Scientific Officer | $1,128,013 |
| Jason Gardner | D.Phil. Former President and Chief Executive Officer | $667,649 |
| Marino Garcia | President and Chief Executive Officer | $496,022 |
| Simrat Randhawa | Chief Medical Officer | $338,158 |
| Ryan Savitz | Chief Financial Officer, Chief Business Officer and Treasurer | $329,651 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jason Gardner | D.Phil. Former President and Chief Executive Officer | $1,654,848 |
| Stephen Mahoney | Former President, Chief Financial and Operating Officer | $1,120,887 |
| Lisa Olson | Former Chief Scientific Officer | $983,504 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jason Gardner | D.Phil. President and Chief Executive Officer | $2,228,102 |
| Thomas Beetham | Chief Legal Officer | $1,894,380 |
| David Nichols | Chief Technical Officer | $1,661,676 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jason Gardner | D.Phil. President and Chief Executive Officer | $3,102,848 |
| Stephen Mahoney | Chief Financial and Operating Officer (7 ) | $1,959,130 |
| John C. Davis | Jr., M.D. Head of Research and Development and Chief Medical Officer | $1,762,160 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jason Ryan | Chief Operating and Financial Officer | $1,940,724 |
| Jason Gardner | D.Phil. President and Chief Executive Officer | $1,651,001 |
| John C. Davis | Jr., M.D. Head of Research and Development and Chief Medical Officer | $913,521 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Jason Gardner | D.Phil. President and Chief Executive Officer | $4,749,458 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Simon Read | Class III director | Appointed | 2025-05-22 |
| Leon O. Moulder, Jr. | member of the Board of Directors | Resigned | 2025-05-22 |
| Sujay Kango | Class II director | Appointed | 2025-03-05 |
| Steven Romano, M.D. | Class III director | Appointed | 2024-09-16 |
| Alison F. Lawton | Class III director | Appointed | 2024-05-28 |
| Leon O. Moulder, Jr. | Class III director | Appointed | 2024-05-28 |
| Ryan Savitz | Treasurer and Chief Financial Officer and principal financial officer | Appointed | 2023-09-12 |
| Edward Carr | Chief Accounting Officer and principal accounting officer | Appointed | 2023-09-12 |
| Marino Garcia | President and Chief Executive Officer and principal executive officer | Appointed | 2023-09-12 |
| Leon O. Moulder, Jr. | Chair of the Board of the Directors | Appointed | 2023-09-12 |
| Jonathan Violin, Ph.D. | Board of Directors | Appointed | 2023-09-12 |
| Lei Meng | Board of Directors | Appointed | 2023-09-12 |
| Paula Soteropoulos | Board of Directors | Appointed | 2023-09-12 |
| Tomas Kiselak | Board of Directors | Appointed | 2023-09-12 |
| Marino Garcia | Board of Directors | Appointed | 2023-09-12 |
| Leon O. Moulder, Jr. | Board of Directors | Appointed | 2023-09-12 |
| Stephen Mahoney | President, Chief Financial and Operating Officer | Terminated | 2023-09-12 |
| Alison F. Lawton | Board of Directors | Appointed | 2023-09-12 |
| Anne McGeorge | Board of Directors | Appointed | 2023-09-12 |
| David T. Scadden, M.D. | Board of Directors | Resigned | 2023-09-12 |
| Michael Vasconcelles, M.D. | Board of Directors | Resigned | 2023-09-12 |
| Amy Lynn Ronneberg | Board of Directors | Resigned | 2023-09-12 |
| Thomas O. Daniel, M.D. | Board of Directors | Resigned | 2023-09-12 |
| Bruce Booth, D. Phil. | Board of Directors | Resigned | 2023-09-12 |
| Jeffrey W. Albers | Board of Directors | Resigned | 2023-09-12 |